13856 research outputs found
Sort by
[[alternative]]Methods for detecting hepatitis B virus surface gene non-sense mutations
No full text[[abstract]]단리된 핵산 샘플에서 소형 S 단백질을 암호화하는 B형 간염 바이러스(HBV) 표면(S) 유전자의 C-말단 절단 돌연변이의 존재를 시험관내 검출하는 방법이 개시되어 있다. 상술한 방법에 사용하기 위한 시험관내 진단 키트도 또한 개시되어 있다
Method and composition for treating Hepatocellular carcinoma without viral infection by controlling the lipid homeostasis
No full text[[abstract]]The present invention relates to a method and a pharmaceutical composition for treating an HCC negative for HBV/HCV, comprising administering a subject in need thereof an therapeutically effective amount of an inhibitory agent to control the genetic alte
雜環化合物及其用途
No full text[[abstract]]本文提供一種式(I)的雜環化合物，也公開了一種包含該雜環化合物之一的藥物組合物。更進一步公開了使用該雜環化合物之一用於驅動造血幹細胞和內皮前驅細胞進入周邊循環的方法，以及用於治療組織傷害、癌症、發炎性疾病、和自體免疫疾病的方法
Heterocyclic compounds and use thereof
No full text[[abstract]]Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds
An integrated testing strategy and online tool for assessing skin sensitization of agrochemical formulations
No full text[[abstract]]Non-animal assessment of skin sensitization is a global trend. Recently, scientific efforts have been focused on the integration of multiple evidence for decision making with the publication of OECD Guideline No. 497 for defined approaches to skin sensitization. The integrated testing strategy (ITS) methods reported by the guideline integrates in chemico, in vitro, and in silico testing to assess both hazard and potency of skin sensitization. The incorporation of in silico methods achieved comparable performance with fewer experiments compared to the traditional two-out-of-three (2o3) method. However, the direct application of current ITSs to agrochemicals can be problematic due to the lack of agrochemicals in the training data of the incorporated in silico methods. To address the issue, we present ITS-SkinSensPred 2.0 for agrochemicals and agrochemical formulations using a reconfigured in silico model SkinSensPred for pesticides. Compared to ITSv2, the proposed ITS-SkinSensPred 2.0 achieved an 11% and 16% improvement in the accuracy and correct classification rate for hazard identification and potency classification, respectively. In addition, an online ITS tool was implemented and available on the SkinSensDB website. The tool is expected to be useful for evaluating skin sensitization of substances
Repurposing linezolid in conjunction with histone deacetylase inhibitor access in the realm of glioblastoma therapies
No full text[[abstract]]Since decades after temozolomide was approved, no effective drugs have been developed. Undoubtedly, blood-brain barrier (BBB) penetration is a severe issue that should be overcome in glioblastoma multiforme (GBM) drug development. In this research, we were inspired by linezolid through structural modification with several bioactive moieties to achieve the desired brain delivery. The results indicated that the histone deacetylase modification, referred to as compound 1, demonstrated promising cytotoxic effects in various brain tumor cell lines. Further comprehensive mechanism studies indicated that compound 1 induced acetylation, leading to DNA double-strand breaks, and induced the ubiquitination of RAD51, disrupting the DNA repair process. Furthermore, compound 1 also exhibited dramatic improvement in the orthotopic GBM mouse model, demonstrating its efficacy and satisfying BBB penetration. Therefore, the reported compound 1, provided with an independent therapeutic pathway, satisfying elongation in survival and tumor size reduction, and the ability to penetrate the BBB, was potent to achieve further development
[[alternative]]Construction of<i> in</i><i> situ</i> modulated controlled growth of MOF-on-mof impedimetric assembly for the practical minimal level assessment of anti-mullerian hormone
No full text[[abstract]]Anti-mullerian hormone (AMH) detection receives much attention since it is used as an ideal biomarker for quantitative assessment of ovarian reserve. The present study proposed a first report on the use of MOF-on-MOF as an electrochemical sensor for recognizing AMH in buffer and serum media. The MOF-on-MOF, MIL-88 B@UiO66NH2 was synthesized by the internal extended growth method (IEGM) involving MIL-88 B on UiO66NH2 by in situ method for the first time. MOF matrix could be established to form a three-dimensional (3D) core-shell hybrid unit using MOFs with distinct characteristics. The morphology, structural characteristics, and electrochemical performance of MIL-88 B@UiO66NH2 were studied. It was successfully used for AMH sensing to demonstrate the detection performance of the internal extended growth method (IEGM) grown MIL-88 B@UiO66NH2 made immunosensor. The electrochemical results indicated that MOF-on-MOF exhibited linear EIS response for AMH concentration varying from 100 ng/mL to 1 fg/mL. Further, the immunosensor displayed high specificity and sensitivity for AMH detection. The fabricated sensor attained a remarkable limit of detection (LOD) of 1.07 fg/mL and 0.82 fg/mL, when studied in PBS and 10% serum buffer media, respectively. The biosensor achieved the limit of quantification (LOQ) of 3.25 fg/mL and 2.5 fg/mL, respectively, when analyzed in PBS buffer and 10% serum buffer. The significant results emphasized that the fabricated biosensor holds a promising potential to act as an appropriate tool for rapid assessment of AMH levels
Is postoperative adjuvant therapy necessary for pT3N0 oral cavity squamous cell carcinoma?
No full text[[abstract]]BACKGROUND: The current NCCN guidelines advocate for the use of adjuvant radiotherapy (RT) or chemoradiotherapy (CRT) in pT3N0 oral cavity squamous cell carcinoma (OCSCC). Here, we sought to evaluate whether postoperative RT/CRT may confer a survival advantage in pT3N0 patients who lack adverse pathological features. METHODS: A dataset of 852 pT3N0 OCSCC patients treated between 2018 and 2021 was analyzed. Patients with adverse pathological features (i.e., positive margins, margins <5 mm, lymphovascular invasion, or perineural invasion) were excluded, leaving 235 eligible patients. The cohort was further refined by omitting 12 patients who received surgery plus chemotherapy and two cases who received RT doses <5000 cGy, resulting in two study groups: surgery alone (n = 131) and surgery plus RT/CRT (n = 90). RESULTS: Baseline characteristics were comparable between groups, except for a higher proportion of buccal subsite (p = 0.0063) and female patients (p = 0.0495) in the surgery alone group. Kaplan-Meier analyses revealed no significant differences in 4-year disease-specific survival (DSS) (84.2 % versus 85.9 %, p = 0.8834) or overall survival (OS) (75.6 % versus 84.8 %, p = 0.2376). These findings were confirmed by multivariable analyses and remained consistent after propensity score matching (n = 74 per group), with similar survival outcomes between groups (4-year DSS, 90.7 % versus 83.2 %, p = 0.4020; 4-year OS, 87.0 % versus 81.9 %, p = 0.6121) CONCLUSIONS: For patients with pT3N0 OCSCC lacking adverse pathological features, the addition of adjuvant RT/CRT does not appear to confer a survival benefit over surgery alone
Artificial intelligence-enhanced electrocardiography improves the detection of coronary artery disease
No full text[[abstract]]An AI-assisted algorithm has been developed to improve the detection of significant coronary artery disease (CAD) in high-risk individuals who have normal electrocardiograms (ECGs). This retrospective study analyzed ECGs from patients aged ≥ 18 years who were undergoing coronary angiography to obtain a clinical diagnosis at Chang Gung Memorial Hospital in Taiwan. Utilizing 12-lead ECG datasets, the algorithm integrated features like time intervals, amplitudes, and slope between peaks, a total of 561 features, with the XGBoost model yielding the best performance. The AI-enhanced ECG algorithm demonstrated high sensitivity (0.82–0.84) when detecting CAD in patients with normal ECGs and gave remarkably high prediction rates among those with abnormal ECGs, both with and without ischemia (92 %-95 % and 80 %-83 %, respectively). Notably, the algorithm's top features, mostly related to slope and amplitude differences, are challenging for clinicians to discern manually. Additionally, the study highlights significant sex differences regarding feature prediction and ranking. Comparatively, the AI-enhanced ECG's detection capability matched that of myocardial perfusion scintigraphy, which is a costly nuclear medicine test, and offers a more accessible alternative for identifying significant CAD, especially among patients with atypical ECG readings
[[alternative]]Anti-human neurotensin receptor 1 antibody and use thereof
No full text[[abstract]]一種分離的抗體，包括：一重鏈可變區（VH），其與SEQ ID NO: 1的胺基酸序列至少75%相同；以及一輕鏈可變區（VL），其與SEQ ID NO: 2的胺基酸序列至少75%相同；其中，該抗體與人神經降壓素受體1（hNTSR1）特異性結合